MedTrace Logo

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2022-12-06

No results posted yet for this study

Summary

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

Conditions

  • Head and Neck Cancer
  • Melanoma
  • HPV-Related Malignancy
  • HPV-Related Carcinoma
  • HPV-Related Cervical Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • Lung Cancer, Nonsmall Cell
  • Melanoma (Skin)

Interventions

DIAGNOSTIC_TEST

Tumor Profiling

Testing TAA and HPV expression. HLA typing.

Sponsors & Collaborators

  • Repertoire Immune Medicines

    lead INDUSTRY

Principal Investigators

  • David Spriggs, MD · Repertoire Immune Medicines

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2022-10-11
Completion
2022-10-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05061940 on ClinicalTrials.gov